Jeremy O. Jones, Ph.D.
Affiliations: | 2005 | Stanford University, Palo Alto, CA |
Area:
Microbiology BiologyGoogle:
"Jeremy Jones"Parents
Sign in to add mentor
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Almahmoud S, Elix CC, Jones JO, et al. (2021) Virtual screening and biological evaluation of PPARγ antagonists as potential anti-prostate cancer agents. Bioorganic & Medicinal Chemistry. 46: 116368 |
Zengin ZB, Dizman N, Salgia N, et al. (2020) Circulating tumor DNA sequencing analysis of patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. 38: e17100-e17100 |
Elix CC, Salgia MM, Otto-Duessel M, et al. (2019) Peroxisome proliferator-activated receptor gamma controls prostate cancer cell growth through AR-dependent and independent mechanisms. The Prostate |
Copeland BT, Du J, Pal SK, et al. (2019) Factors that influence the androgen receptor cistrome in benign and malignant prostate cells. Molecular Oncology |
Salgia MM, Elix CC, Pal SK, et al. (2019) Different roles of peroxisome proliferator-activated receptor gamma isoforms in prostate cancer. American Journal of Clinical and Experimental Urology. 7: 98-109 |
Pal SK, Moreira D, Won H, et al. (2019) Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy. International Journal of Molecular Sciences. 20 |
Pal SK, Tew BY, Lim M, et al. (2019) Mechanistic Investigation of the Androgen Receptor DNA-Binding Domain Inhibitor Pyrvinium. Acs Omega. 4: 2472-2481 |
Copeland B, Du J, Yoo C, et al. (2019) OR34-3 The Androgen Receptor Malignancy Shift Can Be Caused by Mutations Commonly Found in Primary Prostate Cancer Journal of the Endocrine Society. 3 |
Bergerot PG, Arvinitis L, Dizman N, et al. (2019) Assessment of the androgen receptor (AR) activity score versus AR expression in muscle invasive bladder cancer (MIBC). Journal of Clinical Oncology. 37: 463-463 |
Adashek JJ, Won H, Moreira D, et al. (2019) Effect of IL-6 and related mediators on resistance to abiraterone acetate (abi) and enzalutamide (enza) in patients with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 37: 296-296 |